AT-007
DrugTreatment with AT-007 given orally
Other names: aldose reductase inhibitor
NCT Number: NCT04902781
This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
Looking for future studies?
Notify Me2 year–17 year
All sexes
Interventional
Phase 2 / Phase 3
Children's Hospital Colorado, Aurora, Colorado, United States
This is a randomized, double-blind, placebo-controlled study in pediatric subjects with CG. Children with CG ages 2 through 17 years will be enrolled. The study is designed to assess the clinical benefit using validated, standardized Clinical Outcome Assessments (COAs) as well as the safety, PK, and PD (reduction of galactitol levels) of AT-007 in pediatric subjects with CG. The study consists of 2 main parts, Part A and Part B, and an open-label extension (OLE).
Part A is an intra-patient dose escalation evaluating multiple ascending doses (MAD) of AT-007.
Part B is designed to assess the clinical benefits of long-term administration of AT-007 (at the optimum dose identified in Part A) on validated, standardized COAs.
Open-label extension (OLE) is an active treatment extension for patients who received placebo treatment in Part B.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclusion:
Treatment with AT-007 given orally
Other names: aldose reductase inhibitor
Placebo given orally
Time frame: Month 6, Month 12 and Month 18
The primary endpoint is a GST of four components: 1) Behavioral Symptoms Index of the Behavioral Assessment Scale for Children 3 (BASC-3); 2) Activities of Daily Living from the BASC-3; 3) Oral Expression from the Oral and Written Language Skills-II (OWLS-II); 4) Listening Comprehension from the OWLS-II. Each individual component is also a secondary endpoint on their own with the test and scoring described below in the secondary endpoint section. For the GST, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 6, Month 12 and Month 18
Sensitivity Analysis adding the National Institutes of Health Toolbox Cognition Battery (NIH-CB) test which measures cognition. NIH-CB is described below in the secondary endpoints. For the GST with cognition, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 6, Month 12 and Month 18
Sensitivity Analysis adding the National Institutes of Health Toolbox Motor Battery (NIH-MB) 9-Hole Pegboard test which measures fine motor skills. NIH-MB is described below in the secondary endpoints. For the GST with fine motor skills, change from baseline using standardized z-scores is calculated for active versus placebo.
Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18
The change from baseline in plasma galactitol (Pharmacodynamic measure)
Time frame: Month 6, Month 12 and Month 18
Behavioral Assessment System for Children (BASC-3) has a normal range of 40-60 with the higher score showing more difficulty. There are multiple outcome scores included such as: Behavioral Symptoms Index, Activities of Daily Living, Withdrawal, Adapatability, Adaptive Skills, Socialization, and Functional Impairment Index.
Time frame: Month 6, Month 12 and Month 18
Change from baseline in the NIH Toolbox Cognition Battery (NIH-CB). The NIH-CB uses multiple tests to evaluate Cognition and consists of tests of multiple constructs to yield individual ranking and demonstrate Cognitive Function Composite, Fluid Cognition Composite Sequence Memory, List Sorting, Pattern Comparison, and Crystallized Cognition Composite, Picture Vocabulary and Reading Recognition. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.
Time frame: Month 6, Month 12 and Month 18
The Archimedes Spiral Drawing Test evaluates tremor on a scale of 0 (no tremor) to 4 (severe tremor).
Time frame: Month 6, Month 12 and Month 18
NIH Toolbox Motor Battery (NIH-MB) is a multiple of tests to determine fine motor skills using the 9-Hole Pegboard Test and gross motor skills using the Standing Balance Test. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.
Time frame: Month 6, Month 12 and Month 18
Scale for Assessment & Rating of Ataxia (SARA) is 0-40, the higher the score the worse value
Time frame: Month 6, Month 12 and Month 18
Oral and Written Language Scales-II (OWLS-II) has both an Oral Expression and Listening Comprehension score. Scores are 0-100 with a standard deviation of 15.
Time frame: Month 6, Month 12 and Month 18
Onset and severity/progression of cataracts using the Lens Opacity System (LOCS) III, has a grading scale of 1-4, with 4 the most severe as assessed by the reviewer per standard criteria for anterior and posterior obstruction of the eye.
Time frame: Month 6, Month 12 and Month 18
Sexual maturation in female patients as indicated by Tanner Stage 1- 4 which is the ranking of physical development in children, adolescents and adults. This defines physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, and development of pubic hair. This is assessed by physical exam with Stage 1 per-pubescent and Stage 4 post pubescent.
Time frame: Month 6, Month 12 and Month 18
Ovarian function in female patients is recorded by hormonal measures: FSH (follicle stimulating hormone), estradiol, and LH (luteinizing hormone).
Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18
This biomarker analysis will be performed to assess the levels of galactose and its other metabolites; Exploratory Endpoint
Time frame: Month 6, Month 12 and Month 18
Bayley Scales of Infant and Toddler Development (Bayley-4) showing a score of 40 -160 with higher values showing more development. Exploratory Endpoint
Time frame: Month 6, Month 12 and Month 18
Vineland Adaptive Behavior Scales (Vineland-3) has a normal score of 100 and lower scores show developmental delay; Exploratory Endpoint
Applied Therapeutics, Inc.
Industry
A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients With Classic Galactosemia (CG)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03838016
Brain Diseases, Brain Diseases, Metabolic
Tempe, Arizona, United States
View Trial DetailsNCT04117711
Brain Diseases, Brain Diseases, Metabolic
Anaheim, California, United States
View Trial DetailsNCT03580122
Brain Diseases, Brain Diseases, Metabolic
Maastricht, Limburg, Netherlands
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial Details